Tigecycline's Effect on Transaminases
Tigecycline, a glycylcycline antibiotic used for complicated infections, elevates liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in a dose- and duration-dependent manner. Clinical trials show transaminase increases in 15-25% of patients, with levels often 3-5 times upper limit of normal (ULN), peaking around days 7-14 of treatment.[1][2]
Frequency and Severity in Studies
In phase 3 trials (e.g., 878 patients for skin infections, 528 for intra-abdominal infections), any-grade ALT elevation occurred in 22% on tigecycline vs. 19% on comparators; severe cases (>10x ULN) hit 2-3% vs. 1%.[1] Post-marketing data reports rare (<1%) cases of transaminase elevations exceeding 20x ULN, sometimes with jaundice or acute liver injury.[3]
Why Does It Happen?
Tigecycline inhibits mitochondrial protein synthesis, disrupting hepatocyte function and causing direct hepatotoxicity. Risk rises with higher doses (e.g., 100mg loading then 50mg BID) or prolonged use beyond 14 days. No clear link to baseline liver disease, but obesity and IV formulation may contribute.[2][4]
How Long Do Elevations Last?
Levels typically normalize 7-30 days after stopping therapy, even without intervention. Persistent elevation (>8 weeks) is uncommon and warrants monitoring for other causes.[1][3]
Compared to Other Antibiotics
Tigecycline shows higher transaminase risk than comparators like vancomycin+piperacillin-tazobactam (ALT 22% vs. 19%) or imipenem-cilastatin (similar rates but fewer severe cases). Carbapenems or cephalosporins generally have lower hepatotoxicity profiles.[1][5]
Patient Monitoring and Risks
Guidelines recommend baseline LFTs, weekly checks during therapy, and discontinuation if ALT/AST >5x ULN with symptoms (nausea, jaundice). Avoid in severe liver impairment (Child-Pugh C); dose-adjust for moderate (Child-Pugh B). No increased mortality from elevations alone.[4][6]
Alternatives for Liver Concerns
Switch to ertapenem, daptomycin, or linezolid for similar-spectrum coverage with less hepatotoxicity. Biosimilar tetracyclines like omadacycline have comparable but slightly lower ALT rates (15-20%).[5]
Sources
[1] FDA Tigecycline Label
[2] Tygacil Clinical Trials Data
[3] LiverTox: Tigecycline
[4] IDSA Guidelines on Monitoring
[5] Omadacycline vs Tigecycline Trials
[6] Hepatology Reviews on Glycylcyclines